Established in 2019, Shanghai Rily Bioscience Technology Co., Ltd. is a R & D driven enterprise engaged in the research and development of humanized animal models for immune reconstruction and the application of such animal models in immunotherapeutic drugs and in vivo pharmacological efficacy evaluation. The company is committed to becoming an international leading tumor immunology laboratory, a
biopharmaceutical enterprise and institution serving the research and development of new tumor drugs, and helping the development of new tumor drug research and development industry. The founder of the company is a senior returnee immunology expert with profound immunology academic background and in-depth research on nano antibody drug research and development and transgenic disease animal model. After returning home, he has many years of R & D experience in the pharmaceutical R & D industry, is responsible for the construction and operation of the in vivo efficacy platform for tumor immunotherapy, and has rich experience in the construction of PBMC and HSC humanized animal models and the evaluation of IO in vivo efficacy.
